The construction of Tailianxi National Biomedical Cluster was launched to help Healthy China land

On November 19, the 13th China (Taizhou) International Medical Expo opened
.
At the opening ceremony, the launching ceremony
of the construction of the national biomedical cluster of Tairensi was held.

The Ministry of Industry and Information Technology recently announced the winners of the third round of advanced manufacturing cluster finals in China, and the biomedical clusters in Taizhou, Lianyungang and Wuxi occupied a seat
.
It is understood that the cluster industrial foundation in Taizhou, Lianyungang and Wuxi has a strong industrial foundation, with 3199 pharmaceutical enterprises and 498 enterprises on the regulations
.
By the end of 2021, the industrial output value of cluster pharmaceutical enterprises was 304 billion yuan, a year-on-year increase of 15%, accounting for about 9.
02% of the total output value of the industry in the country and nearly 50%
of Jiangsu Province.
In 2021, the cluster added 66 new investment projects of more than 100 million yuan, with a total investment of 55.
97 billion yuan
.

The scene of the launching ceremony Photo by Li Shouyi

According to experts, the selection of the Tailiansir biomedical cluster into the "national team" is well deserved
.
First of all, Taizhou has a unique mechanism of joint construction of China Medical City by ministries and provinces, gathering global well-known enterprises such as Yangzijiang Pharmaceutical, Rico Biotechnology, Nestlé Health, and Shuoshi Biotechnology, and is currently the largest pharmaceutical industrial park with the most complete industrial chain in China, forming leading industries and characteristic industries such as chemical drugs, biological products (vaccines + antibodies, etc.
), diagnostic reagents, modern traditional Chinese medicine, and special formula foods, and the vaccine industry has the highest
concentration in China.

In addition, Taizhou also has "three national only": the only pilot of the great health development of the Yangtze River Economic Belt, the only pilot of industrial agglomeration development of new vaccines and specific diagnostic reagents in the country, and the only pilot of national financial support upgrading and reform in the country
.
Lianyungang has leading enterprises such as Hengrui Pharmaceutical, Haosen Pharmaceutical, Chia Tai Tianqing, Kangyuan Pharmaceutical, etc.
, and has formed significant technical and industrial advantages
in new pharmaceutical fields such as new anti-liver disease and anti-tumor drugs, new traditional Chinese medicines and preparations, and pharmaceutical packaging materials.
Wuxi has gathered leading backbone enterprises such as Fresenius Kabi Huarui Pharmaceutical and Tianjiang Pharmaceutical, and has global competitiveness
in the fields of drug design, clinical trials, CXO (such as CRO and CDMO).
AstraZeneca and WuXi AppTec have industrial layouts
in Taizhou and Wuxi.

Cluster enterprises are strong
.
The cluster has 1 national manufacturing single champion enterprise, 2 global brand pharmaceutical enterprises, 4 enterprises on the list of the best industrial enterprises in China's pharmaceutical R&D product line, 7 enterprises on the list of China's top 100 pharmaceutical industry, 9 national specialized and special new small giant enterprises, 41 listed enterprises, and 301 high-tech enterprises
.

Cluster products have
outstanding advantages.
There are 32 large varieties with annual sales revenue of more than 1 billion yuan
.
The vaccine industry is highly agglomerate, with 14 vaccine companies, and 6 of the 9 vaccine companies that have been mass-produced in Jiangsu Province are concentrated in clusters
.
Since 2021, 21 enterprises in the three places of Tailianxi have won bids for 278 batches of national centralized drug procurement, accounting for 30% of Jiangsu Province and 5%
of the total number of enterprises in the country.

The cluster innovation system is
complete.
In 2021, the cluster R&D investment was 31 billion yuan, accounting for 10.
2% of the sales revenue, and 863 new authorized invention patents were added
.
The cluster has built a support system
for the whole industry chain from molecular design, small-scale and pilot-test, pre-clinical, clinical, large-scale production, and sales.
The cluster has 42 characteristic public service platforms, including 33 at or above the provincial level, and 52 innovation carriers such as national key laboratories and enterprise technology centers
.

It is reported that in the future, through strong cooperation, the Tailianxi biomedical industry cluster will realize the chemical reaction of 1+1+1>3, deepen the high-growth track, improve collaborative policies, promote integrated development, and strive to build a global biomedical R&D and manufacturing highland, the strongest national industrial manufacturing base, and a national advanced manufacturing cluster demonstration zone, providing safe, effective and affordable reassuring drugs
for the people.